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Abstract
Background: Immunoglobulin heavy-and-light-chain amyloidosis (AHL amyloidosis) is a newly established disease
entity where both the immunoglobulin heavy-chain and light-chain compose amyloid fibrils. The immunoglobulins
responsible for the amyloid fibrils are generally identified by immunostaining and/or laser microdissection-liquid
chromatography-tandem mass spectrometry (LMD-LC-MS/MS). However, both techniques do not biochemically
differentiate immunoglobulins that formed amyloid fibrils from non-responsible immunoglobulins.
Case presentation: We herein report a case of 67-year-old female patient with renal amyloidosis due to lymphoplasmacytic
lymphoma secreting monoclonal immunoglobulin M (IgM)-kappa. Renal immunostaining monotypically positive for
IgM-kappa and LMD-LC-MS/MS identification of mu heavy-chain and kappa light-chain were consistent with the
diagnosis of AHL amyloidosis. In order to confirm that both the immunoglobulin heavy-chain and light-chain were
forming amyloid fibrils, we performed LC-MS/MS of renal amyloid fibrils isolated by the traditional amyloid purification
method. The additional LC-MS/MS identified kappa light-chain only without any heavy-chain component. These results
were suggestive that amyloid fibrils were composed by kappa light-chain only and that the mu heavy-chain identified
by immunostaining and LMD-LC-MS/MS was derived from the non-specific co-deposition of monoclonal IgM-kappa.
Conclusion: The case was AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition. While
immunostaining and LMD-LC-MS/MS are irreplaceable techniques to classify amyloidosis, confident exclusion of the
present condition should be required to diagnose AHL amyloidosis.
Keywords: Immunoglobulin light-chain amyloidosis, Immunoglobulin heavy-and-light chain-amyloidosis, Amyloid
purification, Laser microdissection, Mass spectrometry
Background
Amyloidosis is a group of diseases characterised by depos-
ition of insoluble fibrils derived from various proteins [1].
Immunoglobulin related amyloidosis (Ig-amyloidosis) is
one of the most prevalent renal amyloidosis and is classi-
fied into immunoglobulin light-chain (AL) amyloidosis,
immunoglobulin heavy-chain (AH) amyloidosis, and, the
recently established disease entity, immunoglobulin
heavy-and-light-chain (AHL) amyloidosis [1]. Most of the
renal Ig-amyloidosis is AL amyloidosis, whereas AH and
AHL amyloidosis are rare entities [2, 3].
The classification of renal Ig-amyloidosis is generally
performed by immunostaining of immunoglobulin
light-chains and heavy-chains following positive Congo
red stain [1]. Recently, laser microdissection (LMD) of
glomerular amyloid depositions combined with liquid
chromatography-tandem mass spectrometry (LC-MS/MS)
has enabled more accurate classification [1]. In large-scale
studies classifying renal amyloidosis by immunostaining
and LMD-LC-MS/MS [2, 3], the amyloidosis with mono-
typic immunoglobulin light-chain and heavy-chain depos-
ition were described as AHL amyloidosis. Therefore, at
present, amyloidosis with monotypic immunoglobulin
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light-chain and heavy-chain deposition, with greater than
or equal heavy-chain amount, is diagnosed as AHL amyl-
oidosis [3]. However, immunostaining and LMD-LC-MS/
MS do not biochemically differentiate immunoglobulins
that formed amyloid fibrils from non-amyloid, just depos-
ited, immunoglobulins [4, 5]. At the same time, the intact
immunoglobulins could co-deposit with amyloid fibrils
[4–6] and be identified by immunostaining [4, 6] and
LMD-LC-MS/MS [4, 5].
We herein report a case of renal Ig-amyloidosis due to
lymphoplasmacytic lymphoma, with immunostaining and
LMD-LC-MS/MS results consistent with previously
reported AHL amyloidosis [2, 3]. We attempted to
confirm that both the immunoglobulin light-chain and
heavy-chain were forming amyloid fibrils by LC-MS/MS
of renal amyloid fibrils isolated by traditional amyloid
purification method [7]. The additional LC-MS/MS only
identified immunoglobulin light-chains as the component
of amyloid fibrils. This case demonstrated “AL amyloid-
osis with non-amyloid forming monoclonal immuno-
globulin deposition” that might be diagnosed as AHL
amyloidosis by immunostaining and LMD-LC-MS/MS.
Case report
Clinical history and laboratory results
A 67-year-old Japanese woman, taking daily oral cyclo-
phosphamide against lymphoplasmacytic lymphoma for
4 years, was referred to the nephrology department be-
cause of recently developed nephrotic syndrome. The
patient showed bilateral leg edema and weight gain.
Laboratory data showed preserved kidney function
(serum creatinine, 0.61 mg/dL; estimated glomerular
filtration rate, 73.7 ml/min/1.73m2) and hypoalbumin-
emia (2.2 g/dL). The urinalysis was negative for occult
blood and revealed a urinary total protein-to-creatinine
ratio (UPCR) of 9.7 g/gCr. Serum immunoglobulin
levels were IgG 466 mg/dL, IgA 74 mg/dL, and IgM
2789 mg/dL, serum free light-chain levels were
kappa-light chain 24.4 mg/L and lambda-light chain
15.8 mg/L (kappa-to-lambda serum free light-chain ra-
tio of 1.54) and plasma electrophoresis revealed
IgM-kappa monoclonal gammopathy. Renal biopsy was
performed under suspicion of monoclonal gammopathy
of renal significance [1].
Renal biopsy findings and clinical follow-up
The renal biopsy specimens contained 12 glomeruli
without proliferative features, and the glomeruli revealed
slight mesangial widening with amorphous deposits
(Fig. 1a). Congo-red staining was positive in the mesangial
area (Fig. 1b) and electron microscopic analysis showed
non-branched fibrils (Fig. 1c) indicating renal amyloidosis.
Electron microscopic analysis was negative for granular
and amorphous deposits on the endothelial aspect of the
glomerular basement membrane and outer aspect of the
tubular basement membrane. Immunofluorescence stain-
ing was equally positive for IgM (mu heavy-chain, Fig. 1d)
and kappa light-chains (Fig. 1e) and was negative for linear
staining of tubular basement membrane. The immuno-
staining for the other immunoglobulins (Fig. 1f), comple-
ments, serum amyloid A, transthyretin, and fibrinogen
yielded negative results. Therefore, IgM-kappa type renal
Fig. 1 Renal biopsy findings consistent with IgM-kappa type AHL amyloidosis. a Glomeruli with mesangial widening consisting amorphous deposition
(× 100, periodic acid-Schiff stain), (b) Glomeruli with mesangial Congo red positive deposition (× 100), (c) Electron micrograph with mesangial
organized deposition with fibrillary structure of 8 to 12 nm in diameter (× 1500, × 20000), (d-f) Immunofluorescent staining positive for mu heavy-chain (d)
and kappa light-chain (e) and negative for lambda light-chain (F)
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AHL amyloidosis due to lymphoplasmacytic lymphoma
was suspected [1]. Smears and flow cytometry of bone mar-
row aspirate were consistent with previous diagnosis of
lymphoplasmacytic lymphoma. After the diagnosis, weekly
oral fludarabine was initiated. The proteinuria and hypoal-
buminemia gradually improved to UPCR of 2.5 g/gCr and
serum albumin level of 3.6 g/dL in one-and-a-half years.
LC-MS/MS analyses
In order to confirm the monotypic IgM-kappa deposition
and the diagnosis of AHL amyloidosis, we performed
LMD-LC-MS/MS of the glomerular amyloid depositions.
The LMD-LC-MS/MS identified mu heavy-chain and
kappa light-chain (Fig. 2a) with mu heavy-chain predom-
inance consistent with the diagnosis of IgM-kappa type
renal AHL amyloidosis [3]. We next performed LC-MS/
MS of renal amyloid fibrils isolated by the traditional
amyloid purification method [7] to confirm that both the
identified immunoglobulins compose amyloid fibrils. The
additional LC-MS/MS only identified kappa light-chains
without any heavy-chain component (Fig. 2b). All
together, we eventually diagnosed the case as “kappa type
renal AL amyloidosis with non-amyloid forming monoclo-
nal IgM-kappa deposition”.
Discussion
AHL amyloidosis is a disease entity where both the im-
munoglobulin light-chain and heavy-chain are compos-
ing amyloid fibrils, namely the concurrence of AL and
AH amyloidosis [1, 4].
In AL amyloidosis, excess production of amyloido-
genic light-chain lead to amyloid fibril formation [8]. In
the present case, LMD-LC-MS/MS identified the peptide
sequences of the kappa light-chain variable and constant
domain (Fig. 2a), and the LC-MS/MS of isolated amyloid
fibrils confirmed that variable domain were the compo-
nent of the amyloid fibrils (Fig. 2b).
In contrast to AL amyloidosis, little is known about
heavy-chain derived amyloid fibril formation. When
reviewing the reported cases of AH amyloidosis (Table 1,
[2, 3, 9–17]), it was presumable that amyloid fibrils are
composed of the variable domains with or without
Fig. 2 Schematic diagrams of the two-LC-MS/MS analyses. a LMD-LC-MS/MS identified mu heavy-chain and kappa light-chain. The identified
peptide sequences were identical to amino acid position 79–89, 121–128, 132–150, 164–177, 244–238, and 377–391 of mu heavy-chain, position
1–18 and 47–55 of kappa light-chain variable domain, and position 41–75 and 83–99 of kappa light-chain constant domain. b LC-MS/MS of isolated
amyloid fibrils only identified kappa light-chain. The identified peptide sequences were identical to amino acid position 1–18 and 47–55 of kappa
light-chain variable domain
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truncated small constant domains of immunoglobulin
heavy-chain [9, 10, 14–17]. In the present case,
LMD-LC-MS/MS identified peptide sequences that were
broadly distributed among the constant domain (CH1,
CH2, CH3, and CH4 domains) of mu heavy-chain
(Fig. 2a) that do not match the previously reported AH
amyloidosis cases. Therefore, the LMD-LC-MS/MS results
were suggestive that the identified mu heavy-chain was
not composing amyloid fibrils, and the LC-MS/MS of iso-
lated amyloid fibrils confirmed the speculation (Fig. 2b).
There are several hypotheses to explain the glomerular
mu heavy-chain deposition. First, there are reported cases
of AL amyloidosis combined with non-amyloid monoclo-
nal immunoglobulin deposition diseases (MIDDs) [18].
However, in the present case, there were no histological
findings to support the concurrence of non-amyloid
MIDD [1]. Second, concurrence of AL amyloidosis and
heavy-chain disease cannot be denied [19]. However,
plasma electrophoresis did not revealed free heavy-chain
and smears and flow cytometry of the bone marrow aspir-
ate were consistent with the lymphoplasmacytic lymph-
oma without detection of IgM positive light-chain
negative lymphoplasmacytoid lymphocytes [20], There-
fore, we speculate that the identified mu heavy-chain was
derived from monoclonal IgM-kappa that non-specifically
co-deposited with amyloid fibrils [5], while the exact ori-
gin remains unknown.
This case documented “AL amyloidosis with non-amyl-
oid forming monoclonal immunoglobulin deposition”
using immunostaining and two distinct LC-MS/MS ana-
lyses. In fact, the existence of the present condition has
been speculated upon the initial description of AHL amyl-
oidosis [4]. The concern was in part because of the tech-
nical limitations of immunostaining and LMD-LC-MS/
MS which do not differentiate amyloid fibrils from
non-amyloid monoclonal immunoglobulin deposition [4,
5]. Moreover, because of the extremely low prevalence of
AH amyloidosis [2–4, 21], it was questioned whether a
single patient may develop both AL and AH amyloidosis
[4]. On the other hand, co-deposition of non-amyloid im-
munoglobulin with amyloid fibrils is a well-described
phenomenon [4–6, 22]. Therefore, we speculate that the
present condition might not be so rare and might be more
prevalent than “true” AHL amyloidosis.
Conclusion
We demonstrated “AL amyloidosis with non-amyloid
forming monoclonal Ig deposition” disguised as AHL
amyloidosis. The confident exclusion of the present con-
dition should be required to diagnose AHL amyloidosis.
Concise method for the two LC-MS/MS analyses
LMD [2, 3, 18]: Formalin-fixed paraffin-embedded sec-
tions were stained with congo-red dye, and the positive
areas were extracted using an LMD system (LMD 7000;
Leica Microsystems Inc., Tokyo, Japan). The extraction
was solubilised in 10 mM Tris/1 mM EDTA/0.002%
Zwittergent buffer and digested overnight with trypsin.
Amyloid purification [7, 14–17]: Fresh frozen renal tis-
sue was homogenised in Tris-buffered saline, after which
it was centrifuged and the supernatant was decanted.
The procedure was repeated twice. The resultant pellet
was solubilised in 6 M guanidine/0.5 M Tris-buffered sa-
line, after which it was centrifuged and the supernatant
was dialysed against distilled water. The sample was
solubilised in gel loading buffer containing 5%
2-mercaptoethanol and subjected to sodium dodecyl sul-
fate polyacrylamide gel electrophoresis. The entire elec-
trophoresed sample was excited and digested overnight
with trypsin.
The samples were analysed by LC-MS/MS (Nano LC
DiNa; KYA Technologies Co., Tokyo, Japan; and QExactive;
Thermo Fisher Scientific Inc., Waltham, MA).
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